Real-life effectiveness (and cost impact) evaluation of fixed-dose combination fluticasone propionate/formoterol (Flutiform®) for the management of asthma in a routine UK primary care population - Phase 1 (Real-life effectiveness of Flutiform® Phase 1)

First published 28/01/2014

Last updated 17/03/2015

EU PAS number:

EUPAS4872

Study

Finalised

Documents

Study protocol

Initial protocol

2014_01_28 RiRL Napp Study Protocol - Realworld Evaluation of Flutiform_version2_Phase1

English (316.27 KB - PDF) View document

Study results

IPCRG14LB-1326-v2_Final_submitted_edited

English (115.71 KB - PDF) View document

Study report

Other information

Study, other information

R03212a_PCRS abstract_Real world effectiveness Seretide_Napp_2014-06-06_FINAL submitted

English (35.8 KB - PDF) View document

R03212a_REG poster abstract_Real world effectiveness Flutiform_Napp_2014-06-06_FINAL

English (36.75 KB - PDF) View document

Publications

Study publications

Secondary tabs